Skip to content

DE POLDER: value indication

Line	Code	2025	2026	Change	%
Total assets	20/58	€2,993,079	€2,968,089	-€24,990	-0.8%
Fixed assets	21/28	€2,351,351	€2,322,530	-€28,821	-1.2%
Tangible fixed assets	22/27	€2,201,216	€2,172,395	-€28,821	-1.3%
Land and buildings	22	€1,645,440	€1,592,837	-€52,603	-3.2%
Plant, machinery and equipment	23	€113,491	€70,695	-€42,796	-37.7%
Furniture and vehicles	24	€105,214	€197,510	+€92,296	+87.7%
Leasing and similar rights	25	€337,071	€311,352	-€25,719	-7.6%
Financial fixed assets	28	€150,135	€150,135	=	0.0%
Current assets	29/58	€641,728	€645,559	+€3,831	+0.6%
Stocks and contracts in progress	3	€366,527	€366,527	=	0.0%
Stocks	30/36	€366,527	€366,527	=	0.0%
Amounts receivable within one year	40/41	€9,263	€104,084	+€94,821	+1,024%
Trade receivables	40	€9,263	€104,084	+€94,821	+1,024%
Other amounts receivable	41	€0	-	=
Cash at bank and in hand	54/58	€264,651	€159,721	-€104,930	-39.6%
Deferred charges and accrued income	490/1	€1,287	€15,227	+€13,940	+1,083%
Total equity and liabilities	10/49	€2,993,079	€2,968,089	-€24,990	-0.8%
Equity	10/15	€958,306	€1,041,654	+€83,348	+8.7%
Contributions	10/11	€141,109	€141,109	=	0.0%
Capital	10	€141,109	€141,109	=	0.0%
Issued capital	100	€141,109	€141,109	=	0.0%
Revaluation surpluses	12	€13,460	€13,460	=	0.0%
Reserves	13	€803,737	€887,085	+€83,348	+10.4%
Non-distributable reserves	130/1	€14,111	€14,111	=	0.0%
Legal reserve	130	€14,111	€14,111	=	0.0%
Tax-exempt reserves	132	€394,681	€401,794	+€7,113	+1.8%
Distributable reserves	133	€394,945	€471,181	+€76,236	+19.3%
Provisions and deferred taxes	16	€131,560	€133,931	+€2,371	+1.8%
Deferred taxes	168	€131,560	€133,931	+€2,371	+1.8%
Amounts payable	17/49	€1,903,213	€1,792,504	-€110,709	-5.8%
Amounts payable after more than one year	17	€1,223,807	€1,108,110	-€115,696	-9.5%
Financial debts	170/4	€1,223,063	€1,107,367	-€115,696	-9.5%
Other amounts payable	178/9	€744	€744	=	0.0%
Amounts payable within one year	42/48	€678,581	€683,557	+€4,976	+0.7%
Current portion of amounts payable after more than one year	42	€273,384	€323,484	+€50,100	+18.3%
Financial debts	43	€243,110	€220,000	-€23,110	-9.5%
Credit institutions	430/8	€243,110	€220,000	-€23,110	-9.5%
Trade debts	44	€63,943	€36,230	-€27,714	-43.3%
Suppliers	440/4	€63,943	€36,230	-€27,714	-43.3%
Advances received on contracts in progress	46	€0	-	=
Taxes, remuneration and social security	45	€52,485	€25,452	-€27,032	-51.5%
Taxes	450/3	€52,485	€25,452	-€27,032	-51.5%
Other amounts payable	47/48	€45,659	€78,391	+€32,732	+71.7%
Accrued charges and deferred income	492/3	€825	€836	+€11	+1.4%
Non-recurring operating income	76A	€61,474	€101,365	+€39,891	+64.9%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets	630	€232,491	€294,513	+€62,022	+26.7%
Other operating charges	640/8	€40,477	€32,342	-€8,134	-20.1%
Non-recurring operating charges	66A	€31,632	€0	-€31,632	-100%
Gross operating margin	9900	€511,382	€485,353	-€26,029	-5.1%
Operating profit (loss)	9901	€206,782	€158,498	-€48,284	-23.4%
Financial income	75/76B	€141	€0	-€141	-100.0%
Recurring financial income	75	€141	€0	-€141	-100.0%
Financial charges	65/66B	€50,919	€48,569	-€2,350	-4.6%
Recurring financial charges	65	€50,919	€48,569	-€2,350	-4.6%
Profit (loss) for the period before taxes	9903	€156,003	€109,928	-€46,075	-29.5%
Transfer from deferred taxes	780	€5,403	€8,129	+€2,726	+50.5%
Transfer to deferred taxes	680	€5,500	€10,500	+€5,000	+90.9%
Income taxes	67/77	€33,380	€24,209	-€9,170	-27.5%
Profit (loss) for the period	9904	€122,527	€83,348	-€39,178	-32.0%
Transfer from tax-exempt reserves	789	€16,209	€24,387	+€8,179	+50.5%
Transfer to tax-exempt reserves	689	€16,500	€31,500	+€15,000	+90.9%
Profit (loss) for the period to be appropriated	9905	€122,235	€76,236	-€46,000	-37.6%

DE POLDER: value indication

DE POLDER: value indication

Position among the sector peers

What moved between 2025 and 2026

Largest movements

Change in the result, 2025 to 2026

Derived cash bridge

Value

Indicative value of the equity

Adjusted equity

Capitalised earnings

Your EBITDA multiple

Limits of the indication

Next steps